Description:
Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep-wake disorder (often designated as N24HSWD) in totally blind adults. It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, similar to other members of the melatonin receptor agonist class of which ramelteon (2005) and agomelatine (2009) were the first approved.
- Molecular Weight: 245.32
- Molecular Formula: C15H19NO2
Purity: ≥ 99.0%
Canonical SMILES:
CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2
InChI:
InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
InChIKey: PTOIAAWZLUQTIO-GXFFZTMASA-N
- Boiling Point: 442.6±24.0 °C | Condition: Press: 760 Torr
- Melting Point: 57 - 65°C
- Solubility: Chloroform, Methanol
- Appearance: White to off-white Solid
- Application: Tasimelteon is a novel drug, used in the treatment of non-24 hour sleep-wake disorder. It helps to correct the circadian rhythm disorder often seen in patients who are visually impaired.
- Storage: Refrigerator
Synonyms:
BMS-214,778; BMS-214778; BMS214778; BMS 214778. VEC-162; VEC162; VEC 162. Trade name: Hetlioz.
More details are to be found on supplier website
